🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

Report Nature Cancer from Ben Creelan, MD et al describes resistance to #TIL (tumor infiltrating lymphocyte) therapy including loss of subclonal neoantigens targeted by TILs, loss of antigen-specific immune clones, and HLA LOH. nature.com/articles/s4301…

IL-18 making to the clinic! And 3 days manufacturing 🤩 huCART19-IL18 is primed to storm the CAR-T landscape 🌪️

NK-based therapy is one step closer to the clinic! After spending the a good few months researching NK cells for my essay, it’s encouraging to see developments like this one 🙂 #NK #ADCC

Timely breakthrough while I am studying the IEI unit, gene therapy shines for IEIs beyond supportive care. But the key lies in scaling access to bespoke cures for many, if not all. nytimes.com/2025/05/15/hea… nejm.org/doi/full/10.10…

In vivo CAR engineering for immunotherapy bit.ly/45dg5KV

Since I am going to study vaccine this term, I guess cancer vaccine feels like the right way to tune in 🙃

Han Yi flying the National Cancer Centre Singapore flag high at ESMO Breast 😃

Tackling my first scientific academic writing challenge was no small feat, and I’m grateful for the opportunity to contribute under the mentorship of the field’s most brilliant minds John Haanen & team 😊 Expanding TILs beyond melanoma cell.com/med/fulltext/S…

Good to see emerging strategies targeting BTK, MEK, and PI3K–AKT–mTOR pathways to mitigate toxicity & augment CAR-T cell stemness. Metabolic targeting is plausible over manipulating hematopoiesis, hopefully comes with less cytopenias and infections. nature.com/articles/s4157…

Cancer of unknown primary site encompasses a heterogeneous group of metastatic cancers with an unidentified primary site of origin. Putative site-specific therapy and empirical chemotherapy are acceptable treatment options. Read the Clinical Practice article “Cancer of Unknown

Take a look at the next innovations in CAR T cell immunotherapies for cancer! Enjoy reading this review by Dr. Levine (Bruce Levine, Ph.D. 🇺🇦🥼🔬🧬🧪💉) and colleagues. 👇

Gut microbiome, circadian rhythm-based ICI dosing—this era, we’re living IO

🧵1/ T cells have deservedly been in the🔦for #cancer #immunotherapy, but other engineered cell therapies are now📈. What mediates NK cell exhaustion remains an important unanswered❓. 📄Link: nature.com/articles/s4158… I’m so thrilled🥳to share our work out now🚨nature

It’s timely commentary at this age that IL-2 is back in the clinic, but it’s causing anxiety among the clinicians.

A pleasant surprise this weekend — this book was a post-date labour from the COVID era, but it’s finally been delivered at last! 😬 link.springer.com/book/10.1007/9…

🌟Another timely Review Nature Cancer, by G. Dotti and collaborators 👇 doi.org/10.1038/s43018…

Check out a new Review article on clonal hematopoiesis by Jen Trowbridge and collaborators Nature Cancer doi.org/10.1038/s43018…

Our latest Review summarizes the current knowledge on mortality-defining toxicities of #CARTcell therapies, beyond CRS and ICANS. Kai Rejeski & colleagues discuss underlying mechanisms of rare and long-term toxicities and how these affect timing and management, and outline key

This Cell Reports Medicine review addresses the integration of CAR-T cell therapy with reconstructive oncologic surgery in treating peripheral solid tumors, including melanoma, sarcomas, breast cancer, and head and neck cancers. ✅ Check it out! bit.ly/4lUESZe

T cells do the heavy lifting when it comes to the anti-tumor action of checkpoint immunotherapy. But do antibodies play a role too? That’s the question @yile_dai looked to answer in his thesis work, out today in nature! 🧵below nature.com/articles/s4158…